#South Korea #Daejeon #Alteogen #Hybrozyme #ALT-B4

Alteogen Secures Exclusive License for Biologic Product Development

Alteogen Inc., a prominent biopharmaceutical innovator based in South Korea, has made significant strides in its mission to enhance therapeutic delivery systems. On August 5, 2026, the company announced that it has entered into an exclusive licensing agreement with a well-established global pharmaceutical company. This partnership aims to develop and commercialize a subcutaneous biologic product utilizing the innovative Hybrozyme™ technology, specifically through its proprietary compound, ALT-B4 (berahyaluronidase alfa).

This exclusive agreement grants the pharmaceutical firm worldwide rights to advance and sell the new subcutaneous biologic formulation. Alteogen stands to gain considerably from this collaboration, potentially receiving up to $365 million. This figure includes an upfront payment along with milestone payments linked to development stages, regulatory approvals, and sales achievements. Furthermore, Alteogen will also earn royalties based on the net sales generated post-commercialization, creating a lucrative opportunity for the company as it continues to push forward in the biotechnology sector.

The Importance of ALT-B4 Technology

ALT-B4 represents a notable advancement in biopharmaceutical technology. It is designed to convert biologics that typically require intravenous administration into more convenient subcutaneous injections. This transformation can significantly enhance the patient experience by enabling faster, easier administration of therapies that address serious medical conditions.

By utilizing the unique capabilities of ALT-B4, medical professionals can provide effective treatments without the complications associated with IV infusions. The platform temporarily depolymerizes hyaluronan within the extracellular matrix, facilitating the quicker absorption of co-administered drugs, thereby optimizing therapeutic outcomes.

Dr. Tae-Yon Chun, CEO of Alteogen, expressed enthusiasm regarding this strategic partnership. He stated, “We are delighted to enter this agreement with a leading global firm that is committed to advancing innovative therapies for patients facing severe unmet medical needs. Our collaboration will be pivotal in expanding the reach of our platform technology.”

Alteogen’s Commitment to Innovation

Founded in 2008, Alteogen Inc. has dedicated itself to the development and commercialization of groundbreaking biologics, focusing on antibody-drug conjugates, biobetters, and biosimilars. The company's pipeline includes advanced therapeutic formulations and next-generation ADCs developed through proprietary technologies such as NexP™-fusion and NexMab™. Their versatility and expertise in creating hybrid therapeutic options set them apart in the competitive landscape of biopharmaceuticals.

The new licensing agreement marks a crucial step in Alteogen’s growth strategy as it seeks to leverage its technological innovations through partnerships with key players in the global pharmaceutical industry. By streamlining the drug delivery process and enhancing patient compliance through subcutaneous administration, Alteogen is not only improving treatment options but also contributing to the broader field of innovative healthcare.

As they embark on this promising collaboration, both Alteogen and its partner aim to deliver significant advancements in patient care, ensuring that therapies are more accessible and easier to manage. This partnership is expected to impact not just the companies involved but the healthcare landscape as a whole, potentially offering new solutions to patients with critical health challenges.

With the biopharmaceutical industry continually evolving, Alteogen’s proactive approach to licensing and collaboration positions it for sustained success in the future. As development progresses, the medical community and patients alike will be watching closely for updates on the outcomes of this groundbreaking endeavor.